美国食品药品监督管理局（FDA）已正式授予加速批准，同意百时美施贵宝（Bristol Myers Squibb）旗下首款Celmod疗法——Zenbexus™，与达雷妥尤单抗、透明质酸酶-Fihj以及地塞米松联合组成Zdd方案，用于治疗多发性骨髓瘤患者。这一批准适用于从首次复发阶段起，即可启用该疗法。
美国食品药品监督管理局（FDA）已正式授予加速批准，同意百时美施贵宝（Bristol Myers Squibb）旗下首款Celmod疗法——Zenbexus™，与达雷妥尤单抗、透明质酸酶-Fihj以及地塞米松联合组成Zdd方案，用于治疗多发性骨髓瘤患者。这一批准适用于从首次复发阶段起，即可启用该疗法。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.